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LETTER TO THE EDITOR
Response to Ringbaek et al.
Ringbaek and Viskum (p. 271)1 concluded recently:
‘‘our results support a relationship between ipra-
tropium and premature death in patients with
obstructive lung disease.’’ Several points made by
the authors, however, raise questions as to whether
the results truly support this conclusion:
* Our patients who were given ipratropium were
more severe than those who were not. (p. 269)
* Ipratropium users were more frequently pre-
scribed prednisolone. Our adjustment for use
of prednisolone as ‘‘yes’’ or ‘‘no’’ may not
provide a fully sufficient adjustment for the
differences in this marker of severity and risk of
death. (p. 270)
* The increased mortality of all causes observed in
patients with inhaled ipratropium was derived
from an increased risk of COPD death, and lung
cancer death. (p. 266–7)
* We cannot rule out bias due to unmeasured
confounding; e.g., residual confounding by dis-
ease severity. (p. 269)
* An increased risk of dying from cancer was
observed among our COPD patients with ipra-
tropium. The most likely explanation for this
association is residual confounding from tobacco
smoking. (p. 270–1)
Because patients with more severe respiratory
disease are more likely to die from their respiratory
disease, the finding that ipratropium was pre-
scribed preferentially to patients with more severe
respiratory disease is noteworthy. Taken together,
one would expect in this study that patients who
received ipratropium would have increased mor-
tality from respiratory disease. Accordingly, the key
findings are that patients who received ipratropium
died more frequently from lung cancer and
COPD. The authors attribute increased lung cancer
mortality to uncontrolled effects of smoking. A
similar association with COPD mortality, however, is
attributed by the authors to the medication. We
suggest that that the same uncontrolled risk factors
that caused increased lung cancer mortality in this
study also caused increased mortality from COPD.
It should not be surprising that nonrandomized
studies find various respiratory drugs are associated
with increased respiratory mortality.2 Separating
possible effects of drugs from effects of underlying
disease remains a most challenging interpretive
issue in these studies, and highlights the impor-
tance of clinical endpoints in randomized studies.
Ipratropium is one of few respiratory drugs
for which a large randomized study has corrobo-
rated the absence of a relation with increased
mortality.3,4 These results provide reassurance
that, insofar as ipratropium is concerned, it is not
the drug but rather smoking and COPD that increase
mortality.
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